FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

مكتبة البروتيدات

Adamax

Adamantane-Acetyl Peptide

Fat Loss & Body Composition

Adamax is an experimental adamantane-modified peptide compound that has emerged in the performance enhancement and fat loss research space with extremely limited published scientific literature. The adamantane moiety (a diamond-shaped hydrocarbon cage structure) is attached to a peptide backbone to theoretically enhance blood-brain barrier penetration, metabolic stability, and receptor binding affinity. Very little is known about its specific mechanism of action, target receptors, or pharmacological profile due to the near-absence of peer-reviewed research.

mechanism of action

Adamantane-modified peptide designed for enhanced blood-brain barrier penetration and metabolic stability. The adamantane cage structure protects the peptide from enzymatic degradation while improving lipophilicity and cellular uptake for CNS-mediated metabolic effects.

Research Protocols

للاستخدام البحثي فقط. ليس مشورة طبية.

Research protocols are not well-established. Limited published data. Vendor descriptions suggest 200-500mcg daily subcutaneously. Experimental compound with insufficient data for reliable protocol design.

Research Notes

Clinical Research Status

Adamax has no published clinical trials, no regulatory filings, and no formal preclinical development program documented in scientific literature or clinical trial registries. It exists primarily in the gray market of research compounds sold for "research purposes only" without human safety or efficacy data. The compound's origins and development pathway are unclear, with no identified pharmaceutical company or academic institution publicly claiming its creation or characterization.

Key Published Findings

Peer-reviewed literature specifically examining Adamax is essentially nonexistent as of current available databases. The adamantane modification strategy is well-established in pharmaceutical chemistry (examples include amantadine, memantine, and adapalene), where the cage structure improves lipophilicity and metabolic resistance. However, the specific peptide to which the adamantane group is attached in "Adamax" and the resulting pharmacological profile have not been characterized in indexed publications.

Safety Profile

No formal toxicology, pharmacokinetics, or safety studies have been published for Adamax, making any safety claims purely speculative. The adamantane moiety itself has established safety data from approved drugs (amantadine, memantine), but the novel peptide conjugate represents an uncharacterized entity with unknown off-target effects. Users are essentially experimenting with a compound of unknown safety margin, unknown metabolites, and unknown organ toxicity potential.

Comparison to Related Compounds

Without clear mechanistic data, meaningful pharmacological comparison to established fat loss peptides (AOD-9604, tesamorelin) or compounds (GW501516, SR9009) is not possible. The adamantane modification approach distinguishes it structurally from unmodified peptides, potentially offering improved oral bioavailability and CNS penetration. It occupies the same gray market space as other poorly characterized "research compounds" where marketing claims far outpace available scientific evidence.

Community Observations

User reports are sparse and inconsistent, with some claiming enhanced fat oxidation and appetite suppression while others report no noticeable effects. The extremely limited user base and absence of standardized dosing protocols make community anecdotes unreliable for drawing conclusions about efficacy or safety. Most experienced peptide researchers and practitioners recommend against using compounds with this little available safety data when better-characterized alternatives exist.

Half Life

~Unknown

Reconstitution

Bacteriostatic water (BAC)

Storage

Lyophilized

Refrigerate 2-8C.

Reconstituted

Refrigerate 2-8C. Use within 14 days.

US Legal Status

Research chemical (not FDA-approved)

Also Known As

Adamantane-Acetyl Peptide

الأسئلة الشائعة

ما هو Adamax؟

Adamax is an experimental adamantane-modified peptide compound that has emerged in the performance enhancement and fat loss research space with extremely limited published scientific literature. The adamantane moiety (a diamond-shaped hydrocarbon cage structure) is attached to a peptide backbone to theoretically enhance blood-brain barrier penetration, metabolic stability, and receptor binding affinity. Very little is known about its specific mechanism of action, target receptors, or pharmacological profile due to the near-absence of peer-reviewed research.

كيف يعمل Adamax؟

Adamantane-modified peptide designed for enhanced blood-brain barrier penetration and metabolic stability. The adamantane cage structure protects the peptide from enzymatic degradation while improving lipophilicity and cellular uptake for CNS-mediated metabolic effects.

ما هو الوضع التنظيمي لـ Adamax في الولايات المتحدة؟

Research chemical (not FDA-approved)

ما هو عمر النصف لـ Adamax؟

~Unknown

ما الأسماء الأخرى لـ Adamax؟

Adamantane-Acetyl Peptide

Peptide Contacts provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.

Read full disclaimer